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1.1	Introduction




























novel	 function.	 For	 example,	 dopamine	 receptor	 D2R	 and	 somatostatin	 receptor	 SSTR5	 interact	 physically	 through	 hetero-oligomerization,	 resulting	 in	 elevated	 functional	 activity	 in	 response	 to	 dopamine	 and
somatostatin	[3].
Orexin-A	and	 -B,	neuropeptides	secreted	by	orexin	neurons,	bind	 to	 the	GPCRs	orexin	 receptor	1	 (OX1R)	and	2	 (OX2R).	OX1R	primarily	couples	with	Gαq,	whereas	OX2R	couples	with	Gαq,	Gαi,	 and	Gαs
subunits	[4].	Orexin	receptors	are	expressed	in	human	colon	cancer	cell	lines,	and	orexin	stimulation	plays	important	roles	in	regulating	various	behavioral	and	physiological	responses	of	colon	cancer	cells,	including
migration,	proliferation,	and	invasion	[5].
Cholecystokinin	 receptors	 are	 upregulated	 in	many	human	digestive	malignancies.	Clinicopathological	 analysis	 revealed	 that	 elevated	 expression	 of	 the	 cytoplasmic	 cholecystokinin	 receptors	CCK1R	and
CCK2R	correlated	significantly	with	indicators	of	colon	cancer	severity,	including	depth	of	tumor	invasion,	venous	invasion,	and	stage	of	progression	[6].	In	addition,	immunohistochemical	staining	showed	that	nuclear








Human	orexin-A	and	CCK	(26–33)	were	purchased	 from	Phoenix	Pharmaceuticals	 (Belmont,	CA,	USA).	Plasmids	pcDNA3.1-OX1R	and	pcDNA3.1-CCK1R	were	obtained	 from	the	UMR	cDNA	Resource	Center	 (University	of
Missouri-Rolla,	USA).	Lipofectamine	2000	was	obtained	 from	 Invitrogen	 (Grand	 Island,	NY,	USA),	 and	Duolink	 II	 in	 situ	proximity	 ligation	assay	 (PLA)	detection	kits	were	obtained	 from	Sigma-Aldrich	 (St.	Louis,	MO,	USA).	Goat
polyclonal	anti-CCKAR	antibody	(NB100-2805)	was	obtained	from	Novus	Biologicals	(Littleton,	CO,	USA),	Goat	polyclonal	anti-α1B-AR	antibody	(sc-27136)	was	obtained	from	Santa	Cruz	Biotechnology	(Dallas,	TX,	USA),	anti-OX1R
antibody	(ab68718)	was	obtained	from	Abcam	(Cambridge,	UK),	and	anti-HA	and	anti-Myc	antibodies	were	obtained	from	Cell	Signaling	Technology	(Danvers,	MA,	USA).









HIV	 TAT	 (YGRKKRRQRRR)	 was	 fused	 to	 the	 C-termini	 of	 the	 OX1R	 TM5	 and	 TM7	 peptides,	 yielding	 the	 amino	 acid	 sequences	 SCFFFVTYLAPLGLMGMAYFQIFYGRKKRRQRRR	 and















coverslips	 pre-treated	with	 0.1	mg/ml	 poly-D-lysine.	 The	 cells	 were	washed	 three	 times	 for	 5	min	 each	with	 PBS,	 fixed	with	 4%	 paraformaldehyde	 for	 10	min,	 and	 then	 blocked	with	 1%	 bovine	 serum	 albumin	 for	 1	 h	 at	 room


















Method Donor Substrate Donor	Eemission	[nm] Acceptor Acceptor	Eemission	[nm]
BRET1 Rluc Coelenterazine	h 460 eGFP 535
BRET2 Rluc Deep	Blue	C™ 400 GFP2 515
eBRET Rluc EnduRen™ 460 eGFP 535
2.8.2.8	FRET	assays
FRET	assays	were	performed	as	described	[14–16].	Briefly,	the	donor	plasmid	CCK1R-eCFP	and	receptor	plasmid	OX1R-eYFP	were	co-transfected	into	HEK293	cells.	The	donor	and	acceptor	channels	were	used	to	eliminate


















To	 rule	 out	 the	 possibility	 that	 co-expression	 of	 OX1R	 and	 CCK1R	 affects	 the	 expression	 levels	 and	membrane	 distribution	 of	 both	 receptors,	 we	 assessed	 cell	 surface	 expression	 of	 OX1R	 and	CCK1R	 by	 enzyme-linked
immunosorbent	assay	(ELISA)	using	anti-HA	and	-Myc	antibodies,	respectively.	Cell	surface	expression	was	unaffected	by	co-expression	of	both	proteins	in	HEK293	cells	(Fig.	1A).

















































































then	observed	the	activation	patterns	of	Gαq	or	Gαi2	 in	association	with	heterodimers.	BRET2	 signals	 for	Gαq	and	GFP2-Gγ2	 subunits	were	significantly	 reduced	after	 incubation	with	HIV	TAT–fused	TM5,	but	not	TM7,	 following
treatment	of	orexin-A	or/and	CCK	(26–33)	(Fig.	7A).	Orexin-A–induced	Gαi2	activation	was	unexpected	after	incubation	with	HIV	TAT–fused	TM5,	because	OX1R	is	thought	to	couple	to	Gαq,	Gα12,	and	Gα13,	and	orexin-A	is	unable	to




































































































































































at	 a	 1:3	 ratio	 and	 treated	with	 orexin-A,	 in	 cells	 treated	with	 CCK	 (26–33)	 alone,	 and	 in	 cells	 treated	 for	 10	min	with	 orexin-A	 and	 CCK	 (26–33)	 (Fig.	2C).	 The	 BRET	 ratios	 of	 these	 cells	 were
0.364	±	0.010,	0.361	±	0.009,	and	0.366	±	0.012,	respectively.	When	the	experiment	was	repeated	following	energy	donor–acceptor	exchange	between	the	two	receptors,	orexin-A	or/and	CCK	(26–33)-
induced	BRET	ratios	remained	unchanged	(Fig.	2D).	These	results	 implied	that	 ligand	binding	might	not	be	necessary	 for	heterodimerization	of	OX1R	and	CCK1R.	Moreover,	sequential	addition	of
orexin-A	and	CCK	(26–33)	did	not	similarly	alter	the	BRET	ratio	between	OX1R	and	CCK1R	(Fig.	S1).
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Fig.	S2	Heterodimerization	of	OX1R	and	CCK1R	does	not	alter	their	interaction	with	β-arrestins.
HEK293	cells	transiently	co-expressing	CCK1R-Rluc	and	(A,	B)	β-arrestin1-eGFP	or	(C,	D)	β-arrestin2-eGFP	in	the	absence	(A,	C)	or	presence	(B,	D)	of	OX1R	were	monitored	by	extended	BRET	for	10	min	at	37	°C	to	generate	kinetic	curves.	Following
the	addition	of	orexin-A	(100	nM)	and/or	CCK	(26‐–33)	(1000	nM)	or	vehicle,	monitoring	was	continued	for	an	additional	50	min.	Data	represent	the	mean	±	SEM	of	four	independent	experiments.
alt-text:	Fig.	S2
Highlights
• Identification	of	heterodimerization	of	OX1R	and	CCK1R,	with	peptides	corresponding	to	transmembrane	domain	5	of	OX1R	impairing	heterodimer	formation.
• OX1R	forms	heterodimers	with	CCK1R	and	that	G-protein-dependent	signal	transduction	is	reduced	by	orexin-A	and	CCK	(26-33)	co-stimulation.
• Dimerization	of	OX1R	and	CCK1R	may	inhibit	the	Gαq/Gαi/Gα12/Gα13	signaling	pathways
• 	 .
• The	heterodimerization	may	play	an	anti-migratory	role	in	human	colon	cancer	cells.
The	heterodimer	leads	to	decreased	NFAT-RE	activity	and	SRF-RE	activity,	but	still	activate	the	β-arrestin	signaling	pathway
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